A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With Tocilizumab (RoActemra/Actemra)

Hoffmann-La Roche200 enrolled

Overview

This multi-center, non-interventional study will evaluate the pattern of usage in clinical practice, efficacy and safety of tocilizumab in patients with rheumatoid arthritis. Patients initiated on treatment with tocilizumab according to the licensed Canadian product monograph recommendations will be followed for 12 months from the start of treatment.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Rheumatoid Arthritis

Interventions

No interventionOTHER

No intervention administered in this study

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Moderate to severe rheumatoid arthritis according to revised (1987) American college of rheumatology (ACR) criteria * Initiated on tocilizumab treatment by the treating physician in accordance with the Canadian product monograph * Informed consent to data being subject to computerized data processing * Participant must fulfill the reimbursement criteria for treatment with tocilizumab under provincial or private health insurance coverage Exclusion Criteria: * Received tocilizumab prior to enrolment visit * Previously received tocilizumab in a clinical trial or for compassionate use * Enrolled in an ongoing clinical trial and/or received treatment with any investigational agent within 4 weeks, or 5 half-lives of the investigational agent, whichever is longer, before starting treatment with tocilizumab * Participation in another clinical trial or industry sponsored observational study * History of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis, with the exception of concomitant secondary Sjörgen's syndrome

Locations (32)

Unnamed facility

Edmonton, Alberta, Canada

Outcomes

Primary Outcomes

Percentage of Participants on Tocilizumab Treatment at 6 Months After Treatment Initiation

Time frame: At 6 months

Secondary Outcomes

Change From Baseline in Tender Joint Count (TJC)

Following an assessment of 68 joints for tenderness, joints were classified as tender or not tender by the investigator.

Time frame: From baseline to Month 12

Change From Baseline in Swollen Joint Count (SJC)

Following an assessment of 66 joints for swelling, joints were classified as swollen or not swollen by the investigator.

Time frame: From baseline to Month 12

Change From Baseline in Disease Activity Score 28 (DAS28)

The DAS28 scale is a combined index for measuring disease activity in rheumatoid arthritis. Scores range from 0 to 10, with higher scores representing more disease activity.

Time frame: From baseline to Month 12

Change From Baseline in Duration of Morning Stiffness (Visual Analog Scale, VAS)

With VAS, participants specify their level of agreement to a statement by indicating a position along a continuous line between two endpoints, with 0 being the lowest level and 100 being the highest level of morning stiffness.

Time frame: From baseline to Month 12

Change From Baseline in Patient Global Assessment of Disease Activity (Visual Analog Scale, VAS)

Time frame: From baseline to Month 12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Kelowna, British Columbia, Canada

Unnamed facility

Nanaimo, British Columbia, Canada

Unnamed facility

Penticton, British Columbia, Canada

Unnamed facility

Vancouver, British Columbia, Canada

Unnamed facility

Victoria, British Columbia, Canada

Unnamed facility

St. John's, Newfoundland and Labrador, Canada

Unnamed facility

St. John's, Newfoundland and Labrador, Canada

Unnamed facility

Lunenburg, Nova Scotia, Canada

Unnamed facility

Sydney, Nova Scotia, Canada

...and 22 more locations

Change From Baseline in Physician Global Assessment of Disease Activity (Visual Analog Scale, VAS)

With VAS, physicians specify their level of agreement to a statement by indicating a position along a continuous line between two endpoints, with 0 being the lowest level and 100 being the highest level of disease activity.

Time frame: From baseline to Month 12

Change From Baseline in Patient Assessment of Pain (Visual Analog Scale, VAS)

Time frame: From baseline to Month 12

Change From Baseline in Patient Assessment of Fatigue (Visual Analog Scale, VAS)

Time frame: From baseline to Month 12

Change From Baseline in C-Reactive Protein (CRP)

The serum concentration of C-reactive protein (CRP) was measured. A reduction in the level of CRP was considered an improvement.

Time frame: From baseline to Month 12

Change From Baseline in Erythrocyte Sedimentation Rate (ESR)

The erythrocyte sedimentation rate (ESR) was analyzed at the site using the kit provided by the central laboratory. A reduction in the level of ESR was considered an improvement.

Time frame: From baseline to Month 12

Percentage of Participants With Changes in Extra-Articular Manifestations at 12 Months

The extra-articular RA manifestations ascertained were the nodules, Raynaud's phenomenon, secondary Sjogren's syndrome, pulmonary fibrosis, pericarditis, polyneuropathy, scleritis, severe cutaneous vasculitis, weight loss and anemia. Percentages are based on the total number of participants with available data.

Time frame: At 12 months

Number of Participants With Changes in Severity of Extra-Articular Manifestations at 12 Months

The severity of extra-articular RA manifestations ascertained were the nodules, Raynaud's phenomenon, secondary Sjogren's syndrome, pulmonary fibrosis, pericarditis, polyneuropathy, scleritis, severe cutaneous vasculitis, weight loss and anemia. Percentages are based on the total number of participants who responded "YES" to changes in extra- articular RA manifestations (new presence or change in severity) since the last visit. NA=Not applicable

Time frame: At 12 months